Poolbeg Pharma has identified multiple new drug targets for the treatment of influenza.
This marks a “significant” breakthrough in its artificial intelligence programme with medtech company CytoReason.
Poolbeg has been working with CytoReason since March last year.
Disease progression data from Poolbeg’s influenza human challenge trials were combined with CytoReason’s curated disease data.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.